Aligos Therapeutics financials
$5.49−0.90%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.8M | $2.8M | $169.0K | $741.0K | $965.0K | $311.0K | $629.0K | $1.3M | $1.1M | $986.0K | $2.7M | $3.2M |
| Gross profit | $27.8M | $2.8M | $169.0K | $741.0K | $965.0K | $311.0K | $629.0K | $1.3M | $1.1M | $986.0K | $2.7M | $3.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$1.9M | -$26.9M | -$21.8M | -$28.4M | -$18.6M | -$19.2M | -$20.6M | -$20.1M | -$26.4M | -$22.0M | -$25.8M | -$18.0M |
| Net income | -$1.5M | -$23.0M | -$19.9M | -$31.5M | -$15.9M | $43.1M | -$82.2M | -$19.3M | $5.1M | -$34.9M | -$27.9M | -$18.0M |
| Net margin | −5.4% | −814.1% | −11763.9% | −4256.0% | −1643.8% | 13854.7% | −13060.4% | −1517.7% | 477.0% | −3535.8% | −1040.4% | −557.0% |
| Diluted EPS | $-0.14 | $-2.21 | $-1.97 | $-3.04 | $-1.53 | $-2.11 | $-13.09 | $-3.07 | $0.81 | $-5.58 | $-4.12 | $-10.37 |
| EBITDA | -$1.6M | -$26.6M | -$21.6M | -$28.1M | -$18.3M | -$19.0M | -$20.3M | -$19.9M | -$26.2M | -$21.8M | -$25.4M | -$17.7M |
| Operating cash flow | -$24.9M | -$23.1M | -$21.7M | -$24.3M | -$15.5M | -$20.9M | -$18.4M | -$20.1M | -$19.5M | -$22.7M | -$22.7M | -$20.3M |
| Free cash flow | -$25.0M | -$23.2M | -$21.8M | -$24.5M | -$15.6M | -$21.0M | -$18.4M | -$20.1M | -$19.5M | -$22.8M | -$22.7M | -$20.4M |
| Diluted shares | 10.4M | 10.4M | 10.1M | 10.4M | 10.4M | 8.7M | 6.3M | 6.3M | 6.3M | 6.2M | 6.8M | 1.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.4M | $30.0M | $18.3M | $41.9M | $18.7M | $73.8M |
| Short-term investments | $0.00 | $24.9M | $59.5M | $57.1M | $104.3M | $64.1M |
| Total debt | $64.0K | $82.0K | $145.0K | $189.0K | $206.0K | $205.0K |
| Total assets | $66.3M | $64.6M | $88.5M | $109.8M | $134.7M | $150.7M |
| Total liabilities | $34.4M | $32.8M | $35.0M | $37.9M | $32.8M | $34.3M |
| Shareholders' equity | $31.9M | $31.8M | $53.5M | $71.8M | $101.9M | $116.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology